Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

Bicycle Therapeutics (BCYC) Tax Provisions (2018 - 2025)

Historic Tax Provisions for Bicycle Therapeutics (BCYC) over the last 8 years, with Q3 2025 value amounting to $205000.0.

  • Bicycle Therapeutics' Tax Provisions rose 10594.55% to $205000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.2 million, marking a year-over-year increase of 6687.01%. This contributed to the annual value of -$4.8 million for FY2024, which is 15959.98% down from last year.
  • According to the latest figures from Q3 2025, Bicycle Therapeutics' Tax Provisions is $205000.0, which was up 10594.55% from -$231000.0 recorded in Q2 2025.
  • Bicycle Therapeutics' 5-year Tax Provisions high stood at $4.6 million for Q4 2022, and its period low was -$3.4 million during Q3 2024.
  • Moreover, its 5-year median value for Tax Provisions was -$415000.0 (2021), whereas its average is -$319368.4.
  • As far as peak fluctuations go, Bicycle Therapeutics' Tax Provisions crashed by 132727.27% in 2021, and later surged by 106638.66% in 2023.
  • Quarter analysis of 5 years shows Bicycle Therapeutics' Tax Provisions stood at -$785000.0 in 2021, then surged by 680.38% to $4.6 million in 2022, then crashed by 165.54% to -$3.0 million in 2023, then surged by 63.16% to -$1.1 million in 2024, then soared by 118.64% to $205000.0 in 2025.
  • Its last three reported values are $205000.0 in Q3 2025, -$231000.0 for Q2 2025, and -$1.1 million during Q1 2025.